Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinarest New
- Development stage
- Phase 3
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sinarest New is an approved, oral, small-molecule fixed-dose combination tablet manufactured and marketed by Centaur Pharmaceuticals. It contains three active ingredients: paracetamol (500 mg), phenylephrine hydrochloride (10 mg), and chlorpheniramine maleate (2 mg). Paracetamol acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system, thereby reducing pain and fever. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that acts as a nasal decongestant by constricting blood vessels in the nasal passages to relieve congestion and reduce swelling. Chlorpheniramine maleate is a first-generation antihistamine that blocks histamine H1 receptors to alleviate allergy-related symptoms such as runny nose, sneezing, and watery eyes. Sinarest New is indicated for the symptomatic treatment of the common cold, flu, and allergic rhinitis, and may also be used as an adjunct therapy in sinusitis, tonsillitis, and otitis media.
- Brand names
- SinarestSinarest New
- Other names
- Sinarest rangechlorpheniramine maleate + paracetamol + phenylephrine hydrochloride
02
Targets
ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Sinarest New.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinarest New.